11-14-07 CJC

Express Mail No.: EV473972263US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No.: 7,259,247 B1 — Application No.: 09/509,283

Issued: August 21, 2007 — Filed: August 11, 2000

For: ANTI-HUMAN COSTIMULATING T-CELL POLYPEPTIDE MONOCLONAL ANTIBODIES — Attorney Docket No.: 7853-215

REQUEST FOR CERTIFICATE OF CORRECTION

ATTN: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified Patent Deed. The correction is listed on the attached Form PTO-1050.

In claim 14 at column 23, line 47, the term "mouse" should be deleted. This deletion was made by way of an Amendment Under 37 C.F.R. § 1.312 submitted on May 22, 2006 (Exhibit A) and approved for entry by Examiner Ouspenski on June 15, 2006 (Exhibit B).

Accordingly, the requested correction does not involve changes in the patent as would constitute new matter or would require re-examination.

Since the clerical error of the above Patent Deed was made by U.S. Patent and Trademark Office, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 12, 2007

Nikolaos C. George 39,201
Nikolaos C. George (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

by: Lynda Nguyen
Reg. No. 54,338

Express Mail No.: EV473972263US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No.: 7,259,247 B1

Application No.: 09/509,283

Issued: August 21, 2007

Filed: August 11, 2000

For: ANTI-HUMAN COSTIMULATING T-CELL POLYPEPTIDE MONOCLONAL ANTIBODIES

Attorney Docket No.: 7853-215

REQUEST FOR CERTIFICATE OF CORRECTION

ATTN: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified Patent Deed. The correction is listed on the attached Form PTO-1050.

In claim 14 at column 23, line 47, the term "mouse" should be deleted. This deletion was made by way of an Amendment Under 37 C.F.R. § 1.312 submitted on May 22, 2006 (Exhibit A) and approved for entry by Examiner Ouspenski on June 15, 2006 (Exhibit B).

Accordingly, the requested correction does not involve changes in the patent as would constitute new matter or would require re-examination.

Since the clerical error of the above Patent Deed was made by U.S. Patent and Trademark Office, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 12, 2007

Nikolaos C. George 39,201
Nikolaos C. George (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

by: Lynda Nguyen
Reg. No. 54,338

NOV 20 2007

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,259,247 B1

APPLICATION NO.: 09/509,283

ISSUE DATE : August 21, 2007

INVENTOR(S) : Richard Kroczek

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In claim 14 at column 23, line 47, delete "mouse."

MAILING ADDRESS OF SENDER (Please do not use customer number below):

NOV 20 2007

Express Mail No. *EV475142343US*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Richard Kroczek

Confirmation No.: 7620

Application No.: 09/509,283

Group Art Unit: 1644

Filed: August 11, 2000

Examiner: Ouspenski, I.

For: ANTI-HUMAN COSTIMULATNG T-CELL POLYPEPTIDE MONOCLONAL ANTIBODIES

Attorney Docket No.: 7853-215

AMENDMENT UNDER 37 C.F.R. § 1.312

Commissioner for Patents
Mail Stop Issue Fee
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

Please enter the following Amendment and consider the Remarks made herein in connection with the above-captioned application. Applicant submits herewith the Issue Fee Transmittal and, as Exhibit A, a copy of an Interview Summary dated May 18, 2006 between Examiner Ilia Ouspenski and Muna Abu-Shaar.

It is believed that no fee is due in connection with the filing of this Amendment. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.

AMENDMENTS TO THE CLAIMS are reflected in the listing of the claims which begins on page 2 of this paper.

REMARKS begin on page 14 of this paper.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1-70. (Canceled)

71. (Previously presented) A mouse monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

a) is an inducible T cell costimulatory molecule;

b) occurs on two-signal-activated human $CD4^+$ T lymphocytes from human peripheral blood;

c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and

d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody produced by the hybridoma deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH ("DSMZ") and assigned accession no. DSM ACC2539;

and wherein the mouse monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes.

72. (Previously presented) The mouse monoclonal antibody of claim 71, wherein said mouse monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

73. (Previously presented) The mouse monoclonal antibody of claim 71, wherein said mouse monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

74. (Previously presented) The mouse monoclonal antibody of claim 71, wherein said mouse monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

75. (Previously presented) The mouse monoclonal antibody of claim 71, wherein said mouse monoclonal antibody recognizes a human 8F4 polypeptide present on activated human $CD4^+$ T lymphocytes and activated human $CD8^+$ T lymphocytes.

76. (Previously presented) A mouse monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

a) is an inducible T cell costimulatory molecule;

b) occurs on two-signal-activated human $CD4^+$ T lymphocytes from human peripheral blood;

c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and

d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody produced by the hybridoma deposited with the DSMZ and assigned accession no. DSM ACC2539;

wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes,

and wherein the mouse monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

77. (Canceled)

78. (Previously presented) A hybridoma that produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

a) is an inducible T cell costimulatory molecule;

b) occurs on two-signal-activated human $CD4^+$ T lymphocytes from human peripheral blood;

c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and

d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody produced by the hybridoma deposited with the DSMZ and assigned accession no. DSM ACC2539;

and wherein the hybridoma produces a mouse monoclonal antibody that, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes.

79. (Previously presented) The hybridoma of claim 78, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

80. (Previously presented) The hybridoma of claim 78, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

81. (Previously presented) The hybridoma of claim 78, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

82. (Previously presented) The hybridoma of claim 78, wherein said hybridoma produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide present on activated human $CD4^+$ T lymphocytes and activated human $CD8^+$ T lymphocytes.

83. (Previously presented) A hybridoma that produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

a) is an inducible T cell costimulatory molecule;

b) occurs on two-signal-activated human $CD4^+$ T lymphocytes from human peripheral blood;

c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and

d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody produced by the hybridoma deposited with the DSMZ and assigned accession no. DSM ACC2539;

wherein the hybridoma produces a monoclonal antibody,

wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the mouse monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

84. (Canceled)

85. (Previously presented) A pharmaceutical composition comprising a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

a) is an inducible T cell costimulatory molecule;

b) occurs on two-signal-activated human $CD4^+$ T lymphocytes from human peripheral blood;

c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and

d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody produced by the hybridoma deposited with the DSMZ and assigned accession no. DSM ACC2539;

and wherein the pharmaceutical composition comprises a monoclonal antibody that, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes.

86. (Currently amended) A pharmaceutical composition comprising a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

a) is an inducible T cell costimulatory molecule;

b) occurs on two-signal-activated human $CD4^+$ T lymphocytes from human peripheral blood;

c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and

d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody produced by the hybridoma deposited with the DSMZ and assigned accession no. DSM ACC2539;

and wherein the pharmaceutical composition comprises a monoclonal antibody;

wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the ~~mouse~~ monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

87. (Canceled)

88. (Previously presented) A method for producing the mouse monoclonal antibody of claim 71 or 76, comprising: culturing an antibody-secreting hybridoma obtained by:

(i) fusion of a myeloma cell line cell with a spleen cell of a mouse immunized with 2-signal-activated human $CD4^+$ T lymphocytes from human peripheral blood; and

(ii) selection of a hybridoma that produces said antibody,

such that the mouse monoclonal antibody is produced.

89. (Previously presented) The mouse monoclonal antibody of claim 71 or 76, wherein said mouse monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

90. (Previously presented) The mouse monoclonal antibody of claim 71 or 76, wherein said mouse monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

91. (Previously presented) The mouse monoclonal antibody of claim 71 or 76, wherein said mouse monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

92. (Previously presented) The mouse monoclonal antibody of claim 71 or 76, wherein said mouse monoclonal antibody recognizes a human 8F4 polypeptide present on activated human $CD4^+$ T lymphocytes and activated human $CD8^+$ T lymphocytes.

93. (Previously presented) The hybridoma of claim 78 or 83, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

94. (Previously presented) The hybridoma of claim 78 or 83, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

95. (Previously presented) The hybridoma of claim 78 or 83, wherein said hybridoma produces a mouse monoclonal antibody that recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

96. (Previously presented) The hybridoma of claim 78 or 83, wherein said hybridoma produces a mouse monoclonal antibody that recognizes a human 8F4 polypeptide present on activated human $CD4^+$ T lymphocytes and activated human $CD8^+$ T lymphocytes.

97. (Canceled)

98. (Canceled)

99. (Previously presented) A hybridoma cell line deposited with the DSMZ and assigned accession no. DSM ACC2539.

100. (Previously presented) A monoclonal antibody 8F4 produced by the hybridoma cell line of claim 99.

101. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced T lymphocyte proliferation.

102. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced ATAC expression.

103. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD25 expression.

104. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD69 expression.

105. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced TRAP expression.

106. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of T lymphocyte induction of immunoglobulin production by B lymphocytes.

107. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced reduction of apoptosis in activated T lymphocytes.

108. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced T lymphocyte proliferation.

109. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced ATAC expression.

110. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD25 expression.

111. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD69 expression.

112. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced TRAP expression.

113. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of T lymphocyte induction of immunoglobulin production by B lymphocytes.

114. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced reduction of apoptosis in activated T lymphocytes.

115. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced T lymphocyte proliferation.

116. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced ATAC expression.

117. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD25 expression.

118. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced CD69 expression.

119. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced TRAP expression.

120. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of T lymphocyte induction of immunoglobulin production by B lymphocytes.

121. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of 8F4-induced reduction of apoptosis in activated T lymphocytes.

122. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of: 8F4-induced T lymphocyte proliferation, 8F4-induced ATAC expression, 8F4-induced CD25 expression, 8F4-induced CD69 expression, 8F4-induced TRAP expression, T lymphocyte induction of immunoglobulin production by B lymphocytes and 8F4-induced reduction of apoptosis in activated T lymphocytes.

123. (Previously presented) The hybridoma of claim 83, wherein the mouse monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of: 8F4-induced T lymphocyte proliferation, 8F4-induced ATAC expression, 8F4-induced CD25 expression, 8F4-induced CD69 expression, 8F4-induced TRAP expression, T lymphocyte induction of immunoglobulin production by B lymphocytes and 8F4-induced reduction of apoptosis in activated T lymphocytes.

124. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody inhibition of costimulation of T lymphocytes by the human 8F4 polypeptide is exhibited as an inhibition of: 8F4-induced T lymphocyte proliferation, 8F4-induced ATAC expression, 8F4-induced CD25 expression, 8F4-induced CD69 expression, 8F4-induced TRAP expression, T lymphocyte induction of immunoglobulin production by B lymphocytes and 8F4-induced reduction of apoptosis in activated T lymphocytes.

125. (Previously presented) The mouse monoclonal antibody of claim 71, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.

126. (Previously presented) The mouse monoclonal antibody of claim 71, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.

127. (Previously presented) The mouse monoclonal antibody of claim 71, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.

128. (Previously presented) The mouse monoclonal antibody of claim 71, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.

129. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.

130. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.

131. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.

132. (Previously presented) The mouse monoclonal antibody of claim 76, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.

133. (Previously presented) The hybridoma of claim 78, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.

134. (Previously presented) The hybridoma of claim 78, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.

135. (Previously presented) The hybridoma of claim 78, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.

136. (Previously presented) The hybridoma of claim 78, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.

137. (Previously presented) The hybridoma of claim 83, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.

138. (Previously presented) The hybridoma of claim 83, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.

139. (Previously presented) The hybridoma of claim 83, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.

140. (Previously presented) The hybridoma of claim 83, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.

141. (Previously presented) The pharmaceutical composition of claim 85, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.

142. (Previously presented) The pharmaceutical composition of claim 85, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.

143. (Previously presented) The pharmaceutical composition of claim 85, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.

144. (Previously presented) The pharmaceutical composition of claim 85, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.

145. (Previously presented) The pharmaceutical composition of claim 86, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:10,000.

146. (Previously presented) The pharmaceutical composition of claim 86, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:5,000.

147. (Previously presented) The pharmaceutical composition of claim 86, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:2,500.

148. (Previously presented) The pharmaceutical composition of claim 86, wherein the costimulation of proliferation of human T lymphocytes is exhibited at a dilution of OKT-3 of 1:1,000.

149.-153. (Canceled)

154. (Previously presented) The pharmaceutical composition of claim 85, wherein the monoclonal antibody is a mouse monoclonal antibody.

155. (Previously presented) The pharmaceutical composition of claim 86, wherein the monoclonal antibody is a mouse monoclonal antibody.

REMARKS

Claims 71-76, 78-83, 85-86, 88-96, 99-148 and 154-155 are pending and allowed.

Claim 86 has been amended to correct an editorial error by deleting the extraneous term "mouse," which has no antecedent basis, in the last clause of the claim. As evidenced by Exhibit A, a copy of an Interview Summary between Examiner Ilia Ouspenski and Applicant's representative Muna Abu-Shaar, this amendment to claim 86 does not affect the allowability of the claims.

No new matter is added by the Amendment made herein.

CONCLUSION

Applicant respectfully requests that the amendment and remarks made herein be entered and made of record in the file history of the subject application.

Respectfully submitted,

Date: May 22, 2006

Nikolaos C. George 39,201

Nikolaos C. George (Reg. No.)

JONES DAY
222 E. 41st Street
New York, New York 10017
(212) 326-3939

by: Muna Abu-Shaar
L0012

Enclosures

Express Mail No. *EV475142343US*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Richard Kroczek	Confirmation No.: 7620
Application No.: 09/509,283	Group Art Unit: 1644
Filed: August 11, 2000	Examiner: Ouspenski, I.
For: ANTI-HUMAN COSTIMULATNG T-CELL POLYPEPTIDE MONOCLONAL ANTIBODIES	Attorney Docket No.: 7853-215

ok to enter.
I.O.
06/15/2006

AMENDMENT UNDER 37 C.F.R. § 1.312

Commissioner for Patents
Mail Stop Issue Fee
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

Please enter the following Amendment and consider the Remarks made herein in connection with the above-captioned application. Applicant submits herewith the Issue Fee Transmittal and, as Exhibit A, a copy of an Interview Summary dated May 18, 2006 between Examiner Ilia Ouspenski and Muna Abu-Shaar.

It is believed that no fee is due in connection with the filing of this Amendment. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.

AMENDMENTS TO THE CLAIMS are reflected in the listing of the claims which begins on page 2 of this paper.

REMARKS begin on page 14 of this paper.